BioCentury | Jun 19, 2006
Finance

Ebb & Flow

...he’ll focus on private placements and business development. Previously, Cantin was a senior partner at CDP Capital Technology Ventures...
BioCentury | Aug 16, 2004
Company News

Merix board of directors update

...deputy CEO of Aventis Pastuer, a division of Aventis SA; and Richard Meadows, partner at CDP Capital Technology Ventures WIR...
BioCentury | May 10, 2004
Finance

Ebb & Flow

...firm also said it will consolidate its three private equity subsidiaries - CDP Capital Communications, CDP Capital Technology Ventures...
BioCentury | Dec 15, 2003
Finance

Ebb & Flow

Market watchers may have found it strange that CV Therapeutics traded up following Tuesday's bearish FDA panel meeting on CVTX's Ranexa ranolazine to treat chronic angina. But the stock had fallen below cash on Monday,...
BioCentury | Dec 12, 2003
Financial News

Xanthus raises $30.8 million

Cancer company Xanthus (Cambridge, Mass.) raised $30.8 million in a series B round led by Oxford Bioscience. Other investors included CDP Capital - Technology Ventures; Hambrecht & Quist; GIMV; Genechem; China Development Industrial Bank; CDIB BioScience...
BioCentury | Nov 26, 2003
Financial News

Chronogen raises C$17 million

Chronogen (Montreal, Quebec), a developer of therapeutics for age-related degenerative diseases, raised C$17 million in an initial closing of a series B round. The financing was led by Desjardins Venture Capital. Other investors included the...
BioCentury | Nov 10, 2003
Emerging Company Profile

Corporate Profile

Avalon Pharmaceuticals Inc. Germantown, Md. Technology: Expression profiling, chemistry and bioinformatics Disease focus: Cancer Clinical status: NA Founded: 1999 by Kenneth Carter, Alan Walton, Thomas Ried, Brad Lorimier, Thomas David, Meena Augustus, and Jeff Cossma...
BioCentury | Oct 27, 2003
Company News

NanoInk management update

...Ill. Business: Supply/Service Hired: Cedric Loiret-Bernal as president and CEO, formerly a venture advisor at CDP Capital Technology Ventures WIR...
BioCentury | Sep 1, 2003
Company News

Metabolex board of directors update

...Business: Metabolic Appointed: Carl Goldfischer, managing director of Bay City Capital; Sylvain Gareau, partner at CDP Capital Technology Ventures...
BioCentury | Sep 1, 2003
Finance

Ebb & Flow

...current round was co-led by Bay City Capital and new investors Biotech Turnaround Fund and CDP Capital Technology Ventures...
Items per page:
1 - 10 of 17
BioCentury | Jun 19, 2006
Finance

Ebb & Flow

...he’ll focus on private placements and business development. Previously, Cantin was a senior partner at CDP Capital Technology Ventures...
BioCentury | Aug 16, 2004
Company News

Merix board of directors update

...deputy CEO of Aventis Pastuer, a division of Aventis SA; and Richard Meadows, partner at CDP Capital Technology Ventures WIR...
BioCentury | May 10, 2004
Finance

Ebb & Flow

...firm also said it will consolidate its three private equity subsidiaries - CDP Capital Communications, CDP Capital Technology Ventures...
BioCentury | Dec 15, 2003
Finance

Ebb & Flow

Market watchers may have found it strange that CV Therapeutics traded up following Tuesday's bearish FDA panel meeting on CVTX's Ranexa ranolazine to treat chronic angina. But the stock had fallen below cash on Monday,...
BioCentury | Dec 12, 2003
Financial News

Xanthus raises $30.8 million

Cancer company Xanthus (Cambridge, Mass.) raised $30.8 million in a series B round led by Oxford Bioscience. Other investors included CDP Capital - Technology Ventures; Hambrecht & Quist; GIMV; Genechem; China Development Industrial Bank; CDIB BioScience...
BioCentury | Nov 26, 2003
Financial News

Chronogen raises C$17 million

Chronogen (Montreal, Quebec), a developer of therapeutics for age-related degenerative diseases, raised C$17 million in an initial closing of a series B round. The financing was led by Desjardins Venture Capital. Other investors included the...
BioCentury | Nov 10, 2003
Emerging Company Profile

Corporate Profile

Avalon Pharmaceuticals Inc. Germantown, Md. Technology: Expression profiling, chemistry and bioinformatics Disease focus: Cancer Clinical status: NA Founded: 1999 by Kenneth Carter, Alan Walton, Thomas Ried, Brad Lorimier, Thomas David, Meena Augustus, and Jeff Cossma...
BioCentury | Oct 27, 2003
Company News

NanoInk management update

...Ill. Business: Supply/Service Hired: Cedric Loiret-Bernal as president and CEO, formerly a venture advisor at CDP Capital Technology Ventures WIR...
BioCentury | Sep 1, 2003
Company News

Metabolex board of directors update

...Business: Metabolic Appointed: Carl Goldfischer, managing director of Bay City Capital; Sylvain Gareau, partner at CDP Capital Technology Ventures...
BioCentury | Sep 1, 2003
Finance

Ebb & Flow

...current round was co-led by Bay City Capital and new investors Biotech Turnaround Fund and CDP Capital Technology Ventures...
Items per page:
1 - 10 of 17